C-CAM 1 is a cell adhesion molecule of the immunoglobulin supergene family. We showed that C-CAM 1 plays critical roles in prostate cancer initiation and progression and that loss of C-CAM 1 is an early event in prostate carcinogenesis. More importantly, we showed that reintroduction of C-CAM 1 into prostate cancer cells can reverse their cancerous growth and that reduction of C-CAM 1 expression, by C-CAM I antisense transfection, in nontumorigenic prostate epithelial cells induces their tumorigenicity. These results indicate that C-CAM 1 is a tumor suppressor. Although C-CAM1 expression in DU145 prostate cancer cells effectively inhibits in vivo tumor growth in mice, there is no significant difference in in vitro cell proliferation between control and C-CAM1-expressing cells. Thus, C-CAM1 expression may inhibit tumor growth by interfering with tumor interactions with host environment. Because angiogenesis is essential for the growth and progression of solid tumors, we hypothesized that C-CAM I acts by inhibiting tumor angiogenesis. We have preliminary data demonstrating that expression of C-CAM 1 in prostate cancer cells induces the release of a factor (C-CAM 1-induced factor (CIF)) that has strong antiangiogenic effects both in vitro and in vivo. Our preliminary results suggest that this anti-angiogenic effect is mediated by induction of endothelial cell apoptosis. C-CAM1 is therefore a promising target for prostate cancer therapy. Preclinical studies of a recombinant human C-CAM1 adenovirus revealed that it can markedly suppress prostate tumorigenicity. To fully exploit C-CAM I's therapeutic potential, it is essential to determine how C-CAM I suppresses tumors. In addition, combining C-CAM 1 therapy with existing therapies should produce more effective treatment. Therefore, we propose the following Specific Aims:
AIM #1 : To purify, identify, and clone CIF.
AIM #2 : To study whether a synergistic antitumor activity can be achieved by combining C-CAM1 with another antiangiogenic agent, TNP-470. Achieving these aims will provide valuable information for applying CCAM1 for prostate cancer therapy and for developing C-CAM1 combination therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA086342-02
Application #
6514552
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Wolpert, Mary K
Project Start
2001-03-01
Project End
2005-02-28
Budget Start
2002-03-01
Budget End
2003-02-28
Support Year
2
Fiscal Year
2002
Total Cost
$168,750
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Pathology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Tu, Shi-Ming; Lin, Sue-Hwa; Podoloff, Donald A et al. (2010) Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol 8:341-51
Tu, Shi-Ming; Lin, Sue-Hwa (2008) Current trials using bone-targeting agents in prostate cancer. Cancer J 14:35-9
Cheng, Chien-Jui; Ye, Xiang-cang; Vakar-Lopez, Funda et al. (2007) Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5:675-84
Tu, Shi-Ming; Kim, Jeri; Pagliaro, Lance C et al. (2005) Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23:7904-10
Lee, Sok-Hyong; Nishino, Michiya; Mazumdar, Tuhina et al. (2005) 16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway. Cancer Res 65:7984-92
Najjar, Sonia M; Yang, Yan; Fernstrom, Mats A et al. (2005) Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab 2:43-53
Vakar-Lopez, Funda; Cheng, Chien-Jui; Kim, Jeri et al. (2004) Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203:688-95
Abou-Rjaily, George A; Lee, Sang Jun; May, Denisa et al. (2004) CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation. J Clin Invest 114:944-52
Phan, Dillon; Cheng, Chien-Jui; Galfione, Matthew et al. (2004) Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. Cancer Res 64:3072-8
Lin, Sue-Hwa; Nishino, Michiya; Luo, Weiping et al. (2004) Inhibition of prostate tumor growth by overexpression of NudC, a microtubule motor-associated protein. Oncogene 23:2499-506

Showing the most recent 10 out of 13 publications